• How It Works
    • History
    • How It Works
    • FAQ
    • Values
    • ESG Commitment
    • Definitions
  • Portfolio
  • Latest Articles

CBD

May 25th

Neurotech Demonstrates Potential Benefits for Management of Multiple Sclerosis Disease

  Archived
Revenue generating BDA sets its sights on US market

March 17th 2021

Revenue generating BDA sets its sights on US market

Neurotech expands exclusive license to include all neurological disorders

March 2nd 2021

Neurotech expands exclusive license to include all neurological disorders

Neurotech’s key near-term objectives

January 21st 2021

Neurotech’s key near-term objectives

$2M in repeat purchase orders display Creso Pharma’s growth potential

October 13th 2020

$2M in repeat purchase orders display Creso Pharma’s growth potential

How (and why) companies are mixing Terpenes into Cannabis Distillates

May 29th 2020

How (and why) companies are mixing Terpenes into Cannabis Distillates

Creso Pharma set to expand human health product line with technological breakthrough

February 6th 2020

Creso Pharma set to expand human health product line with technological breakthrough

Roots extends sales relationship with Israeli cannabis company

February 5th 2020

Roots extends sales relationship with Israeli cannabis company

BPH investee signs JV with cutting edge cannabis researcher

January 28th 2020

BPH investee signs JV with cutting edge cannabis researcher

Page 1 of 5 next >

Connect with us

EXPLORE

  • Finfeed Portfolio
  • Latest Articles
  • How It Works
  • Archived Articles
  • About StocksDigital
  • News
  • PORTFOLIOS

  • Next Investors
  • Catalyst Hunter
  • Wise-Owl
  • STOCKS

    FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS
      CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY  
    The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).
    © 2021   |   AFSL (CAR No.433913)